La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Sanofi Crescita futura

Future criteri di controllo 2/6

Sanofi prevede che gli utili e i ricavi cresceranno rispettivamente di 18.6% e 5.1% all'anno. Si prevede che l'EPS crescerà di 19.1% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 14.1% in 3 anni.

Informazioni chiave

18.6%

Tasso di crescita degli utili

19.1%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	17.7%
Tasso di crescita dei ricavi	5.1%
Rendimento futuro del capitale proprio	14.1%
Copertura analitica	Good
Ultimo aggiornamento	19 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Aug 17

These 4 Measures Indicate That Sanofi (EPA:SAN) Is Using Debt Reasonably Well

Apr 13

Previsioni di crescita degli utili e dei ricavi

ENXTPA:SAN - Stime future degli analisti e dati finanziari passati (EUR Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	53,487	9,823	10,598	12,807	16
12/31/2025	50,529	8,845	9,542	11,509	19
12/31/2024	47,280	6,797	7,529	9,663	19
6/30/2024	47,080	4,216	4,138	8,118	N/A
3/31/2024	46,288	4,538	N/A	N/A	N/A
12/31/2023	46,033	5,400	7,234	10,258	N/A
9/30/2023	45,699	9,066	N/A	N/A	N/A
6/30/2023	46,045	8,617	8,107	10,264	N/A
3/31/2023	46,199	8,357	N/A	N/A	N/A
12/31/2022	45,389	8,371	8,325	10,526	N/A
9/30/2022	44,348	6,409	N/A	N/A	N/A
6/30/2022	42,039	6,643	7,594	9,620	N/A
3/31/2022	40,342	6,666	N/A	N/A	N/A
12/31/2021	39,175	6,223	8,479	10,522	N/A
9/30/2021	38,496	6,174	N/A	N/A	N/A
6/30/2021	37,546	5,777	5,827	8,219	N/A
3/31/2021	36,939	12,197	N/A	N/A	N/A
12/31/2020	37,369	12,294	5,335	7,418	N/A
9/30/2020	37,650	11,224	N/A	N/A	N/A
6/30/2020	37,692	11,138	6,834	8,491	N/A
3/31/2020	38,234	3,453	N/A	N/A	N/A
12/31/2019	37,631	2,855	5,928	7,715	N/A
9/30/2019	36,940	3,179	N/A	N/A	N/A
6/30/2019	36,763	3,591	4,958	6,953	N/A
3/31/2019	36,264	4,439	N/A	N/A	N/A
12/31/2018	35,677	4,319	3,570	5,547	N/A
9/30/2018	35,316	4,041	N/A	N/A	N/A
6/30/2018	34,985	3,243	4,815	6,596	N/A
3/31/2018	35,428	3,539	N/A	N/A	N/A
12/31/2017	36,221	3,773	N/A	7,379	N/A
9/30/2017	36,400	4,593	N/A	N/A	N/A
6/30/2017	36,315	4,744	N/A	8,133	N/A
3/31/2017	35,677	4,682	N/A	N/A	N/A
12/31/2016	34,696	4,395	N/A	7,838	N/A
9/30/2016	34,349	4,195	N/A	N/A	N/A
6/30/2016	34,115	4,154	N/A	8,122	N/A
3/31/2016	34,569	4,440	N/A	N/A	N/A
12/31/2015	34,861	4,411	N/A	8,920	N/A
9/30/2015	37,201	5,292	N/A	N/A	N/A
6/30/2015	32,910	4,628	N/A	8,561	N/A
3/31/2015	35,074	4,329	N/A	N/A	N/A
12/31/2014	31,999	4,273	N/A	7,690	N/A
9/30/2014	33,484	4,112	N/A	N/A	N/A
6/30/2014	33,134	4,140	N/A	7,463	N/A
3/31/2014	33,074	3,812	N/A	N/A	N/A
12/31/2013	31,291	3,639	N/A	6,954	N/A
9/30/2013	33,424	3,127	N/A	N/A	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di SAN ( 18.6% all'anno) è superiore al tasso di risparmio ( 1.2% ).

Guadagni vs Mercato: Si prevede che gli utili di SAN ( 18.6% all'anno) cresceranno più rapidamente del mercato French ( 12.2% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di SAN cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di SAN ( 5.1% all'anno) crescerà più lentamente rispetto al mercato French ( 5.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di SAN ( 5.1% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di SAN sarà basso tra 3 anni ( 14.1 %).

Sanofi Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates fall by 17%

Consensus EPS estimates increase by 13%

Recent updates

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Sanofi Ships U.S. Influenza Vaccines for the 2024/25 Season

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Sanofi to Present New Data from its Hemophilia Portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Sarclisa Accepts for FDA Priority Review for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Upcoming dividend of €3.76 per share

Sanofi Announces Board and Committee Appointments

Sanofi Announces Board and Committee Appointments

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 17%

Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger

These 4 Measures Indicate That Sanofi (EPA:SAN) Is Using Debt Reasonably Well

Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups

Sanofi Announces Phase 2b Results for Amlitelimab Support Potential for Best-In-Class Maintenance of Response in Atopic Dermatitis

Full year 2023 earnings: EPS and revenues miss analyst expectations

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Consensus EPS estimates increase by 13%

Sanofi Reports Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2023

New minor risk - Profit margin trend

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sanofi Announces CFO Changes, Effective April 1, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita